Ellevest Inc’s Supernus Pharmaceuticals SUPN Stock Holding History

Ellevest Inc’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-37	Closed	-$1K	–	1325
2020 Q1	$1K	Buy	+37	New	+$778	﹤0.01%	981

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Ellevest Inc's SUPN Position: Q2 2020 in Review

Ellevest Inc sold out of Supernus Pharmaceuticals (SUPN) in Q2 2020, closing a stake of 37 shares — an estimated $1K sold.

Ellevest Inc first reported a position in SUPN in Q1 2020 and held it in 1 quarter. The position peaked at $1K in Q1 2020. 218 funds tracked by Wall St. Rank hold SUPN as of Q2 2020.

Ellevest Inc reported no remaining Supernus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Ellevest Inc sold 37 Supernus Pharmaceuticals shares in Q2 2020, an estimated $1K.
Ellevest Inc first reported a position in Supernus Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Ellevest Inc's Supernus Pharmaceuticals position peaked at $1K in Q1 2020.
218 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2020.

Based on Ellevest Inc's 13F filing for Q2 2020, filed 6 Jul 2020.